Caladrius Biosciences Equity 2024

Caladrius Biosciences Aktienanalyse

What does Caladrius Biosciences do?

Caladrius Biosciences Inc was founded in 1980 as a pharmaceutical biotechnology company and is headquartered in Basking Ridge, New Jersey. The company focuses on developing cellular therapies for the treatment of serious diseases. Caladrius Biosciences aims to improve the lives of patients with unmet medical needs by developing novel and innovative therapies based on neuroscientific, immunological, and regenerative approaches. The business model of Caladrius Biosciences is based on researching and developing products that focus on the needs of patients. The goal is to concentrate on innovative and groundbreaking therapies that can treat diseases that have not been adequately treated before. The company has developed a portfolio of groundbreaking products based on stem cell, immune, and regenerative therapies. Caladrius Biosciences has three different business areas: - The first business area is its subsidiary PCT, LLC, which offers clinical manufacturing services in the field of clinical cell therapies. The subsidiary provides a scalable platform for the production of individual cell-based therapies. - The second business area is conducting clinical trials, including in the field of cardiovascular diseases. Caladrius Biosciences collaborates closely with clinics, doctors, and other professionals to demonstrate the potential of its own products through clinical studies. - The third area is the development of innovative therapies for diseases that previously could not be treated. The company is working on regenerative, immunological, and stem cell therapies. Caladrius has various products in development based on novel technologies, such as stem cell therapy. The company focuses on cardiovascular diseases, autoimmune diseases, and cancer. One of the flagship products of the company is CLBS201, which is a stem cell treatment for coronary heart disease. It is an autologous cell-based product derived from a patient's bone marrow and is used in combination with angioplasty, a minimally invasive surgical procedure to widen narrowed or blocked blood vessels. In summary, Caladrius Biosciences Inc is a leading biopharmaceutical company that focuses on developing innovative stem cell and immune therapies for the treatment of serious diseases. The company prioritizes the needs of patients and has established a unique position in the regenerative and cell-based therapy industry. Caladrius Biosciences pursues a long-term and sustainable growth model by relying on innovative technologies and clinical trials to continue developing groundbreaking products. In short, Caladrius Biosciences tirelessly works to improve the lives of people and cure diseases that were previously considered incurable. Caladrius Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Caladrius Biosciences's Equity

Caladrius Biosciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Caladrius Biosciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Caladrius Biosciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Caladrius Biosciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Caladrius Biosciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Caladrius Biosciences Stock

What is the equity of Caladrius Biosciences this year?

Caladrius Biosciences has equity of 66.58 M USD this year.

What was the equity of Caladrius Biosciences compared to the previous year?

The equity of Caladrius Biosciences has increased/decreased by -27.83% decreased compared to the previous year.

What impact does a high equity have on investors of Caladrius Biosciences?

A high equity is advantageous for investors of Caladrius Biosciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Caladrius Biosciences?

A low equity can be a risk for investors of Caladrius Biosciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Caladrius Biosciences affect the company?

An increase in equity of Caladrius Biosciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Caladrius Biosciences affect the company?

A reduction in equity of Caladrius Biosciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Caladrius Biosciences?

Some factors that can affect the equity of Caladrius Biosciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Caladrius Biosciences so important for investors?

The equity of Caladrius Biosciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Caladrius Biosciences take to change the equity?

To change equity, Caladrius Biosciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Caladrius Biosciences pay?

Over the past 12 months, Caladrius Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Caladrius Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Caladrius Biosciences?

The current dividend yield of Caladrius Biosciences is .

When does Caladrius Biosciences pay dividends?

Caladrius Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Caladrius Biosciences?

Caladrius Biosciences paid dividends every year for the past 0 years.

What is the dividend of Caladrius Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Caladrius Biosciences located?

Caladrius Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Caladrius Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Caladrius Biosciences from 5/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/26/2024.

When did Caladrius Biosciences pay the last dividend?

The last dividend was paid out on 5/26/2024.

What was the dividend of Caladrius Biosciences in the year 2023?

In the year 2023, Caladrius Biosciences distributed 0 USD as dividends.

In which currency does Caladrius Biosciences pay out the dividend?

The dividends of Caladrius Biosciences are distributed in USD.